Design of new and sensitive fluorogenic substrates for human kallikrein hK3 (prostate-specific antigen) derived from semenogelin sequences

被引:17
作者
Réhault, S
Brillard-Bourdet, M
Bourgeois, L
Frenette, G
Juliano, L
Gauthier, F
Moreau, T
机构
[1] Univ Tours, INSERM, EMI U 00 10, Enzymol & Prot Chem Lab, F-37032 Tours, France
[2] CHUL, Res Ctr, Hormonal Bioregulat Lab, Ste Foy, PQ, Canada
[3] Univ Laval, Ste Foy, PQ G1K 7P4, Canada
[4] Univ Fed Sao Paulo, Escola Paulista Med, Dept Biofis, BR-04044020 Sao Paulo, Brazil
来源
BIOCHIMICA ET BIOPHYSICA ACTA-PROTEIN STRUCTURE AND MOLECULAR ENZYMOLOGY | 2002年 / 1596卷 / 01期
关键词
human kallikrein; prostate-specific antigen; semenogelin; substrate specificity; chymotrypsin-like enzyme;
D O I
10.1016/S0167-4838(02)00204-2
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Human kallikrein hK3 (prostate-specific antigen) is a chymotrypsin-like serine protease which is widely used in the diagnosis of prostate cancer. Assays of the enzymatic activity of hK3 in extracellular fluids have been limited by a lack of sensitive synthetic substrates. This report describes the design of a series of internally quenched fluorescent peptides containing an amino acid sequence based on preferential hK3 cleavage sites in semenogelins. Those were identified by 2-D gel electrophoresis analysis and N-terminal sequencing of semenogelin fragments generated by ex vivo proteolysis in freshly ejaculated semen. These peptides were cleaved by hK3 at the C-terminal of certain tyrosyl or glutaminyl residues with k(cat)/K-m values of 15 000-60 000 M-1 s(-1). The substrate Abz-SSIYSQTEEQ-EDDnp was cleaved at the Tyr-Ser bond with a specificity constant k(cat)/K-m of 60000 M-1 s(-1), making it the best substrate for hK3 described to date. (C) 2002 Elsevier Science B.V. All rights reserved.
引用
收藏
页码:55 / 62
页数:8
相关论文
共 46 条
[1]   THE CHYMOTRYPSIN-LIKE ACTIVITY OF HUMAN PROSTATE-SPECIFIC ANTIGEN, GAMMA-SEMINOPROTEIN [J].
AKIYAMA, K ;
NAKAMURA, T ;
IWANAGA, S ;
HARA, M .
FEBS LETTERS, 1987, 225 (1-2) :168-172
[2]   Clinical value of human glandular kallikrein 2 and free and total prostate-specific antigen in serum from a population of men with prostate-specific antigen levels 3.0 ng/mL or greater [J].
Becker, C ;
Piironen, T ;
Pettersson, K ;
Hugosson, J ;
Lilja, H .
UROLOGY, 2000, 55 (05) :694-699
[3]   The diagnostic and prognostic utility of prostate-specific antigen for diseases of the breast [J].
Black, MH ;
Diamandis, EP .
BREAST CANCER RESEARCH AND TREATMENT, 2000, 59 (01) :1-14
[4]   Serpin-derived peptide substrates for investigating the substrate specificity of human tissue kallikreins hK1 and hK2 [J].
Bourgeois, L ;
BrillardBourdet, M ;
Deperthes, D ;
Juliano, MA ;
Juliano, L ;
Tremblay, RR ;
Dube, JY ;
Gauthier, F .
JOURNAL OF BIOLOGICAL CHEMISTRY, 1997, 272 (47) :29590-29595
[5]   Use of the percentage of free prostate-specific antigen to enhance differentiation of prostate cancer from benign prostatic disease - A prospective multicenter clinical trial [J].
Catalona, WJ ;
Partin, AW ;
Slawin, KM ;
Brawer, MK ;
Flanigan, RC ;
Patel, A ;
Richie, JP ;
deKernion, JB ;
Walsh, PC ;
Scardino, PT ;
Lange, PH ;
Subong, ENP ;
Parson, RE ;
Gasior, GH ;
Loveland, KG ;
Southwick, PC .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1998, 279 (19) :1542-1547
[6]   INTRAMOLECULARLY QUENCHED FLUOROGENIC TETRAPEPTIDE SUBSTRATES FOR TISSUE AND PLASMA KALLIKREINS [J].
CHAGAS, JR ;
JULIANO, L ;
PRADO, ES .
ANALYTICAL BIOCHEMISTRY, 1991, 192 (02) :419-425
[7]   ENZYMATIC-ACTIVITY OF PROSTATE-SPECIFIC ANTIGEN AND ITS REACTIONS WITH EXTRACELLULAR SERINE PROTEINASE-INHIBITORS [J].
CHRISTENSSON, A ;
LAURELL, CB ;
LILJA, H .
EUROPEAN JOURNAL OF BIOCHEMISTRY, 1990, 194 (03) :755-763
[8]   Substrate specificity of prostate-specific antigen (PSA) [J].
Coombs, GS ;
Bergstrom, RC ;
Pellequer, JL ;
Baker, SI ;
Navre, M ;
Smith, MM ;
Tainer, JA ;
Madison, EL ;
Corey, DR .
CHEMISTRY & BIOLOGY, 1998, 5 (09) :475-488
[9]   Structural and energetic determinants of the S1-site specificity in serine proteases [J].
Czapinska, H ;
Otlewski, J .
EUROPEAN JOURNAL OF BIOCHEMISTRY, 1999, 260 (03) :571-595
[10]  
Denmeade SR, 1997, CANCER RES, V57, P4924